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Abstract
Background Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with acute heart failure (AHF). 
The presence of AF is associated with adverse prognosis in patients with chronic heart failure (CHF) but little is known 
about its impact in AHF.
Methods Data were collected between April 2007 and March 2013 across 185 (> 95%) hospitals in England and Wales from 
patients with a primary death or a discharge diagnosis of AHF. We investigated the association between the presence of AF 
and all-cause mortality during the index hospital admission, at 30 days and 1 year post-discharge.
Results Of 96,593 patients admitted with AHF, 44,642 (46%) were in sinus rhythm (SR) and 51,951 (54%) in AF. Patients 
with AF were older (mean age 79.8 (79.7–80) versus 74.7 (74.5–74.7) years; p < 0.001), than those in SR. In a multivari-
able analysis, AF was independently associated with mortality at all time points, in hospital (HR 1.15, 95% CI 1.09–1.21, 
p < 0.0001), 30 days (HR 1.13, 95% CI 1.08–1.19, p < 0.0001), and 1 year (HR 1.09, 95% CI 1.05–1.12, p < 0.0001). In 
subgroup analyses, AF was independently associated with worse 30-day outcome irrespective of sex, ventricular phenotype 
and in all age groups except in those aged between 55 and 74 years.
Conclusion AF is independently associated with adverse prognosis in AHF during admission and up to 1 year post-discharge. 
As the clinical burden of concomitant AF and AHF increases, further refinement in the detection, treatment and prevention 
of AF-related complications may have a role in improving patient outcomes.
Keywords Acute heart failure · Atrial fibrillation · Prognosis · Mortality
Introduction
Atrial fibrillation (AF) is the commonest sustained arrhyth-
mia in patients with heart failure (HF) with a prevalence 
reported between 30–50% in contemporary studies [1–4]. 
Previous studies have shown that the presence of AF in 
patients with HF is associated with an adverse prognosis, 
although many of these studies have reported this associa-
tion in patients with chronic stable HF [5]. A meta-analysis 
including 50,000 patients suggested that the presence of AF 
was associated with increased mortality risk in both ran-
domised controlled studies and observational studies, irre-
spective of left ventricular (LV) function [6]. It appears that 
the risk is greatest in patients with incident AF compared to 
those with prevalent AF, RR: 2.21 versus 1.19, respectively 
[7]. However, the prognostic impact of AF in patients admit-
ted with an acute heart failure (AHF) is less clear [8–10].
Analysis of 10,701 patients hospitalised with an AHF 
as part of the EuroHeart Failure survey suggested that the 
presence of chronic AF did not impact in-hospital mortality 
(OR 0.84; 95% CI 0.69–1.00) although new-onset AF was 
an independent predictor of in-hospital mortality (OR 1.53, 
95% CI 1.14–2.06) [11]. In contrast, in an analysis of 99,810 
patients from 255 sites admitted with HF enrolled in Get 
With The Guidelines-Heart Failure (GWTG-HF) program 
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in the United States, the presence of AF was an independ-
ent predictor of in-hospital mortality (OR 1.17, 95% CI 
1.05–1.29; p < 0.005) [7], whilst one other study has shown 
AF to be associated with worse outcomes in patients with 
AHF with underlying ischaemic heart disease (IHD) only 
[12]. Previous studies have not reported whether the prog-
nostic impact of AF in patients admitted with an AHF is 
similar in patients with HFREF (Heart Failure with Reduced 
Ejection Fraction) and HFPEF (Heart Failure with Preserved 
Ejection Fraction), across genders or different age groups or 
have only reported in-hospital mortality outcomes with no 
post-discharge outcomes studied [7, 13–15].
We have, therefore, studied the association between AF 
and in-hospital and longer term mortality outcomes in an 
unselected cohort of patients admitted with an AHF in 
England and Wales through analysis of the National Heart 
Failure Audit. Furthermore, we aimed to examine whether 
the observed association differs in patients with HFPEF and 
HFREF.
Methods
The current study dataset is derived from around 150,000 
patients hospitalised with heart failure and thus provides 
an excellent opportunity to study the clinical characteristics 
and outcomes in a ‘real-world’ setting. Mortality tracking 
is undertaken by the Medical Research Information Service 
using a patient’s National Health Service (NHS) number, 
which provides a unique identifier for any person registered 
with the NHS in England and Wales, and the Office for 
National Statistics.
Study population
The National HF audit (NHFA) established in 2007 to moni-
tor and improve care and treatment of patients is one of the 
largest HF cohorts in the world. 145 out of 150 NHS Trusts 
in England and Health Boards in Wales (97%) submitted 
data to the audit between April 2012 and March 2013. The 
audit collects information from unscheduled individuals who 
have been admitted to participating hospitals with a primary 
death or discharge with a coded diagnosis of heart failure. 
This is designated by the following ICD codes: I11.0 hyper-
tensive heart disease with (congestive) heart failure; I25.5 
ischaemic cardiomyopathy; I42.0 dilated cardiomyopathy; 
I42.9 cardiomyopathy, unspecified; I50.0 congestive heart 
failure; I50.1 left ventricular failure or I50.9 heart failure, 
unspecified. The National Heart Failure Audit has developed 
a minimum data standard, in an attempt to ensure that the 
records submitted to the audit are fit for purpose.
For patients with more than one reported hospital admis-
sion, we randomly selected one admission. The analyses 
were restricted to patients with a diagnosis of atrial fibril-
lation or sinus rhythm on an ECG performed during the 
admission. Patients aged less than 18 years, duplicate 
records, no ECG data to clarify rhythm status and missing 
outcome data were excluded from the study (supplement 
Fig. 1). Evident moderate or severe left ventricular systolic 
dysfunction are derived from results of echocardiography, 
or other gold standard tests (including MRI, nuclear scan) 
during the current admission or in the 12 months prior to 
admission. Death was defined as mortality from any cause. 
Patients aged younger than 18, with missing records of ECG 
data or outcome data and those with no life status recorded 
were excluded.
Primary outcome
The primary outcomes were all-cause mortality as an inpa-
tient, at 30 days, 1 year and all deaths.
Covariates
The National Health Service (NHS) information centre 
designed a secure, encrypted and web-based database called 
Lotus Notes for the recording of data relating to patients 
with heart failure which consisted of 233 fields. For the pur-
pose of NHFA, 21 fields were assigned as core fields from 
this database and seven fields contained basic demographic 
information such as patient unique identifiers, gender and 
date of enrolment. The data were collected and recorded 
with the help of heart failure specialist nurses during each 
admission from patient case notes. Full details about selec-
tion of variables in this dataset and NHFA list of core fields 
are published elsewhere [16, 17].
Statistical methods
The analysis was performed using the Stata/MP 13.1 statisti-
cal software (College Station, TX). The cohort was stratified 
into two groups, those with sinus rhythm and those with 
atrial fibrillation. Where an individual had multiple admis-
sions we randomly selected a single hospital episode. Con-
tinuous variables are presented as mean or 95% confidence 
intervals (CI), or median (interquartile range). Categorical 
variables are presented as counts (%). We tested for differ-
ences between the groups using Chi-squared tests for non-
parametric data and Student’s t test for normally distributed 
continuous variables.
We estimated hazard ratios (HRs) for mortality within 
30-day using Cox regression with shared frailty or cluster 
models. A shared-frailty model is the survival-data analog to 
regression models with random effects and is used to model 
within-group correlation. Each hospital was assigned as a 
group variable within the model.
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Covariates in multivariable models
Multivariable adjustment included the continuous variables 
age as well as index of multiple deprivations and dichot-
omised categorical variables (yes versus no): sex (female 
versus male), history of myocardial infarction, hyperten-
sion, type 2 diabetes, ischaemic heart disease, valvular heart 
disease, LVH on echocardiography, and renal impairment. 
Other categorical variables included place of care, follow-
up care, NYHA class and peripheral oedema. Separate sub-
group analyses for LVSD, diastolic HF on echocardiography 
and gender as well as their interactions with the presence or 
absence of AF were performed.
To understand the association between age, sex, the inter-
action between age and sex, rhythm status and risk of all-
cause mortality at 1 year, we used the margins command in 
Stata to estimate margins of responses for specified values 
of covariates and present the results as a plot. Margins are 
statistics calculated from predictions of a previously fitted 
model (for example, a multivariable logistic regression) at 
fixed values of some covariates and averaging or otherwise 
integrating over the remaining covariates.
Sensitivity analyses were performed on models deter-
mined from the imputed data. Multiple imputations with 
chained equations were used to impute missing data. Five 
imputations were generated. Propensity score matching with 
nearest-neighbour matching was performed on the imputed 
cohort to create matched groups for presence or AF or sinus 
rhythm were used to estimate hazard ratios for mortality at 
30-day, 1-year and full follow-up. We assessed the impact 
of heart rate as an effect modifier in a separate multivariable 
model. We employed the Stata module stddiff to estimate the 
standardised difference between groups It has been proposed 
that an absolute standardised difference of 0.10 or more indi-
cates that covariates are imbalanced between groups [18].
Study findings are reported in accordance with the 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) recommendations [19]. No eth-
ics approval was needed for this analysis; the National Heart 
Failure Audit was conducted with the approval of the NHS 
Information Centre.
Results
A total of 168,843 patients were admitted with AHF in Eng-
land and Wales between January 2007 and December 2013. 
Supplemental Fig. 1 illustrates a flowchart of eligibility and 
exclusion of patients included in the analysis. After exclu-
sions, 96,593 records were available for analyses, of which 
44,642 patients were in SR (46.5%) and 51,951 (53.5%) in 
AF.
Table 1 outlines the distribution of patient’s charac-
teristics by rhythm status. Patients with AF were signifi-
cantly older than those with sinus rhythm [mean age 79.8 
(79.7–80.0) vs 74.7 (74.5–74.7) years; p < 0.0001] and had 
a lower prevalence of diabetes, ischaemic heart disease and 
left ventricular systolic dysfunction (LVSD). The mean heart 
rate was greater in patients with AF 90 (89.5–90.3)] versus 
those with SR 84.0 (83.5–84.4); p < 0.0001.
Table 2 illustrates differences in treatments, follow-up 
and mortality outcomes. Patients with AF were less likely 
to be prescribed an ACE inhibitor or ARB, but more likely 
Fig. 1  Crude KM survival 
estimates
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to be prescribed a B-blocker or a diuretic. No statistically 
significant difference was observed in median length of stay 
between the two cohorts [9 (IQR 4–17) versus 8 (IQR 4–15) 
days in patients with AF and SR, respectively].
Patients with SR were more likely to be managed in a 
cardiology ward and be followed up either by a heart fail-
ure service or a cardiologist (Table 2). In-hospital mortality 
was greater in patients with AF (11.5%) compared to those 
patients with sinus rhythm (8.6%; p < 0.0001) with similarly 
worse outcomes at 30 days (17.4% vs 13.5%, p < 0.0001) and 
1 year (36.6% vs 30.0%, p < 0.0001). Figure 1 illustrates the 
crude Kaplan–Meier survival curves of both cohorts. Fig-
ure 2 in supplement shows variation in all-cause mortality 
by year of discharge from 2007 to 2013 and it remains highly 
consistent in AHF patients who have AF as compared to 
those who are in sinus rhythm.
Multivariable analyses were undertaken to assess rela-
tionships between admission rhythm, clinical outcomes and 
in-hospital, 30-day (Supplement Table 1) and 1-year mor-
tality (Tables 3, 4, 5; Fig. 2). The presence of AF was inde-
pendently associated with mortality at all time points stud-
ied; in-hospital (HR 1.15, 95% CI 1.09–1.21, p < 0.0001), 
30-day (HR 1.13, 95% CI 1.08–1.19, p < 0.0001) and 1-year 
(HR 1.09, 95% CI 1.05–1.12, p < 0.0001) outcomes. Finally, 
Fig. 3 illustrates the relationship between atrial fibrillation 
and mortality across gender, the presence of LVSD, diastolic 
Table 1  Distribution of patient 
characteristics by heart rhythm 
status
Column percentages are presented
p values from Student’s t tests, two-sample test of proportions or Chi-squared tests for differences in pro-
portions for atrial fibrillation versus sinus rhythm respectively
AMI acute myocardial infarction, IHD ischaemic heart disease, NYHA New York Heart Association, LVSD 
left ventricle systolic dysfunction
a Only 20,976 participants had heart rate data recorded of which 9400 were in sinus rhythm and 11,576 
were in AF
b Due to missing data, the percentages reported are from these totals
Variable Atrial fibrillation Sinus rhythm
Totalb 51,951 (53.8) 44,642 (46.2)
Age (years) 96,593 79.8 (79.7–80.0) 74.7 (74.5–74.7) < 0.0001
Age categories (years)
 Min-54 5749/96,593 1521 (2.9) 4228 (9.5) < 0.0001
 55–64 8552/96,593 3299 (6.3) 5253 (11.8) < 0.0001
 65–74 18,524/96,593 8845 (17.0) 9679 (21.7) < 0.0001
 75–84 34,238/96,593 19,623 (37.8) 14,615 (32.7) < 0.0001
 85 + 29,530/96,593 18,663 (36.0) 10,867 (24.3) < 0.0001
Sex
 Male 52,271/96,552 28,059 (54.0) 24,212 (54.3) 0.4925
 Female 44,281/96,552 23,870 (46.0) 20,411 (45.7) 0.5277
Previous AMI 27,276/89,601 12,538 (26.3) 14,738 (35.1) < 0.0001
History of diabetes 27,267/92,550 13,315 (26.9) 13,952 (32.4) < 0.0001
History of hypertension 49,972/90,884 27,189 (55.9) 22,783 (53.9) < 0.0001
History of IHD 42,387/90,874 21,690 (44.8) 20,697 (48.7) < 0.0001
History of valvular heart disease 19,641/88,285 12,158 (25.8) 7483 (18.2) < 0.0001
NYHA class
 Class I 5,294/88,888 2177 (4.6) 3117 (7.5) < 0.0001
 Class II 14,850/88,888 7348 (15.4) 7502 (18.2) < 0.0001
 Class III 39,210/88,888 21,316 (44.8) 17,894 (43.3) < 0.0001
 Class IV 29,534/88,888 16,717 (35.2) 12,817 (31.0) < 0.0001
Peripheral oedema
 None 21,022/86,660 8965 (19.4) 12,057 (29.9) < 0.0001
 Mild 22,267/86,660 11,752 (25.4) 10,515 (26.0) < 0.0001
 Moderate 28,041/86,660 16,061 (34.7) 11,980 (29.7) < 0.0001
 Severe 15,330/86,660 9,513 (20.5) 5,817 (14.4) < 0.0001
Moderate or severe  LVSDa 54,475/79,724 27,577 (65.2) 26,898 (71.9) < 0.0001
 Heart rate (bpm) 20,976 90.0 (89.5–90.3) 84.0 (83.5–84.4) < 0.0001
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dysfunction and age. AF was independently associated with 
worse 30-day mortality outcomes in all subgroups studied, 
except patients aged 55–64 and 65–74, where statistical 
trends that were not significant were observed (HR 1.04 
95% CI 0.85–1.29, p = 0.69 and HR 1.09 95% CI 0.97–1.22).
The impact of heart rate as an effect modifier is assessed 
in a separate multivariable model. Only around a quarter 
of the study population had heart rate data recorded. We 
assessed the standardised difference between groups (of 
individuals who had heart rate recorded (n = 20,976) and 
those who did not have heart recorded, n = 75,617) for both 
continuous and categorical variables. A table of these stand-
ardised differences are presented in Supplement Table 2. The 
impact of increased HR was assessed in a series of models 
in the 20,976 patients who had the data. Increased heart rate 
(HR increase by 10 beats per min) is associated with high 
inpatient deaths but lost its significance for long-term mor-
tality (Supplement Tables 3, 4). AF is independently associ-
ated with adverse prognosis whether HR data are recorded 
or not in separate multivariable Cox regression models on 
imputed data. (Supplement Tables 5, 6). However, in a mul-
tivariable model from propensity score-matched (PSM) data 
in those with HR data, the adverse significant effect of AF 
was lost, likely due to type 2 errors from the small numbers 
present in model (Supplement table 7).
We assessed the interaction of gender or age with AF 
and its impact on 1-year mortality in a separate multivari-
able logistic regression analysis and results are presented in 
Table 2  Treatment, follow-up 
and mortality status by heart 
rhythm status
Column percentages are presented
p values from Student’s t tests, two-sample test of proportions or Chi-squared tests for differences in pro-
portions for atrial fibrillation versus sinus rhythm respectively
MRA mineralocorticoid receptor antagonist, ARB angiotensin receptor blockers, ACI angiotensin-convert-
ing enzyme inhibitor, IQR interquartile range
Variable Atrial fibrillation Sinus rhythm p value
Total
Treatment medications
 MRA 29,402/80,939 (36.3) 15,776 (36.7) 13,626 (35.9) 0.017
 ARB 11,651/74,027 (15.7) 6091 (15.5) 5560 (16.0) 0.058
 ACE inhibitor 50,168/79,171 (63.4) 25,821 (61.6) 24,347 (65.4) < 0.0001
 ACE inhibitor OR ARB 61,165/80,903 (75.6) 31,598 (73.8) 29,567 (77.6) < 0.0001
 Beta-blocker 53,262/80,864 (65.9) 28,546 (66.3) 24,716 (65.3) 0.003
 Thiazide diuretic 3647/79,869 (4.6) 2136 (5.0) 1511 (4.1) < 0.0001
 Digoxin 20,719/81,510 (25.4) 18,107 (40.9) 2612 (7.0) < 0.0001
 Loop diuretic 77,373/87,151 (88.8) 42,291 (90.9) 35,082 (86.4) < 0.0001
Median length of stay in days (IQR) 8 (4–16) 9 (4–17) 8 (4–15) < 0.0001
Discharge medications
 Beta-blocker 36,494/58,282 (62.6) 19,193 (62.7) 17,301 (62.6) < 0.0001
 Digoxin 15,134/58,514 (25.8) 13,185 (42.2) 1949 (7.2) < 0.0001
 Loop diuretic 55,140/62,531 (88.2) 29,820 (90.3) 25,320 (85.8) < 0.0001
 Thiazide 2558/58,385 (4.4) 1493 (4.8) 1065 (3.8) < 0.0001
 ARB 8305/54,425 (15.3) 4307 (15.0) 3998 (15.5) < 0.0001
 MRA 20,285/58,548 (34.6) 10,776 (35.1) 9509 (34.2) 0.025
 ACE inhibitor 36,326/57,635 (63.0) 18,468 (61.2) 17,858 (65.1) < 0.0001
 ACE inhibitor OR ARB 44,125/58,709 (75.2) 22,541 (73.3) 21,584 (77.2) < 0.0001
Main place of care
 Cardiology 43,290/95,963 (45.1) 21,952 (42.5) 21,338 (48.1) < 0.0001
 General medicine 42,203/95,963 (44.0) 23,777 (46.1) 18,426 (41.6) < 0.0001
 Other 10,470/95,963 (10.9) 5905 (11.4) 4565 (10.3) 0.0735
Follow-up
 Heart failure liaison service 43,807/88,852 (47.3) 22,303 (46.9) 21,504 (52.0) < 0.0001
 Palliative care 3,822/87,934 (4.4) 2242 (4.8) 1579 (3.8) < 0.0001
 Care of the elderly 12,279/88,951 (13.8) 6859 (14.4) 5420 (13.1) < 0.0001
 Cardiology 42,497/89,885 (49.3) 21,127 (44.0) 21,370 (51.0) < 0.0001
 GP follow-up 62,072/89,298 (69.5) 33,107 (69.2) 28,965 (69.8) 0.055
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the form of margin plots (Supplement Fig. 3). Essentially, 
adverse effects of age and male gender on HF patients who 
have AF are minimal up to 60 years of age compared to 
those in sinus rhythm but increases clearly after it.
Discussion
In this large multicentre national heart failure registry, we 
demonstrate that the presence of AF in patients admitted 
with an AHF is independently associated with an increased 
risk of in-hospital, 30-day and 1-year mortality. This rela-
tionship is observed in both HFREF and HFPEF, across gen-
ders and across different age groups in multivariate analyses.
These are the first data assessing the prognosis of AF in 
AHF during index hospital admission, 30 days and 1 year 
after discharge with detailed analysis in clinically important 
subgroups. The NHFA is one of the largest HF registries 
in the world providing more pragmatic real-world data as 
compared to post hoc analysis of clinical trials which are 
conducted in controlled clinical settings. No prior studies 
have evaluated the effect of AF in AHF patients across both 
genders and different age groups in the short and longer 
terms. Our study demonstrates significant differences in 
all clinical outcomes between patients with sinus rhythm 
and AF. Patients with HF who were found to be in AF have 
fewer comorbidities on presentation, prolonged hospital 
stay and worse short- and long-term mortalities in multi-
variable analysis. The results of this study are in contrast to 
previous smaller studies where AF was not associated with 
adverse long-term outcomes. For instance, in the Danish 
Investigations of Arrhythmia and Mortality on Dofetilide 
(DIAMOND) study (3587 patients), the authors reported 
similar in-hospital mortality between patients presenting 
in AF and sinus rhythm [12]. An analysis of the national 
GWTG-HF registry data (99,810 patients from 255 sites 
of US) also demonstrated a clear association between AF 
and mortality in hospitalised heart failure patients but no 
post-discharge follow-up data were available [7]. Our study 
represents a more contemporary cohort of patients (years 
of data collection 2007–2013) as compared to previously 
published research work (EHFS1 2000–2001, GWTG-HF 
2005–2010, ASCEND-HF 2007–2010) [7, 11, 20]. Further-
more, our study also provides important information about 
processes of care in the treatment of these high-risk patients 
for the first time, such as their main place of care during 
hospital and post-discharge follow-up. It is pertinent to note 
that majority of these high-risk group patients with AF are 
neither treated in a cardiology ward (44%) nor followed up 
in cardiology clinics after discharge (47%). This finding is 
important and may provide a mechanism that contributes 
to our observations that patients with AF have adverse out-
comes particularly in the longer term as previous work has 
demonstrated improved survival if HF patients are treated in 
cardiology wards or are followed up in either heart failure or 
cardiology clinics [21].
The relationship between AF and HF was first described 
in the literature almost 100 years ago [22]. This associa-
tion could be explained to some extent by the presence of 
common risk factors such as age, diabetes, hypertension, 
Fig. 2  Hazard ratios for mortal-
ity from multivariate analysis 
for atrial fibrillation versus 
sinus rhythm at different time 
points (imputed data)
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high BMI, valvular, ischaemic and structural heart disease 
[23]. These risk factors contribute to myocardial cellular and 
extracellular damage, neurohormonal and electrophysiologi-
cal changes which predispose the heart to AF and heart fail-
ure [24, 25]. The increased resting and exaggerated exercise 
heart rate response in AF predisposes to shorter diastolic 
filling time which leads to a reduction in cardiac output [26]. 
Furthermore, loss of effective atrial contraction also contrib-
utes to reduce diastolic filling. AF is considered the most 
common cause of tachycardia-induced cardiomyopathy. 
In a similar way, HF can increase the risk for the develop-
ment of AF by raising cardiac filling pressures, autonomic 
Table 3  Multivariate analyses for relation between AF (versus sinus 
rhythm) and 1-year mortality on imputed data of patients recorded as 
HF, (N = 96,593)
HR hazard ratio, CI confidence interval, ECG electrocardiograph, 
NYHA New York Heart Association, AMI acute myocardial infarc-
tion, GP general practitioner, IHD ischaemic heart disease, LVH left 
ventricular hypertrophy, ARB angiotensin receptor blockers, ACI 
angiotensin-converting enzyme inhibitor
HR 95% CI p value
Atrial fibrillation on ECG 1.09 1.05 1.12 < 0.001
Breathlessness
 NYHA I 1.00
 NYHA II 1.05 0.96 1.16 0.292
 NYHA III 1.16 1.06 1.27 0.002
 NYHA IV 1.30 1.19 1.42 0
Peripheral oedema
 None 1.00
 Mild 1.08 1.02 1.14 0.01
 Moderate 1.23 1.17 1.30 < 0.0001
 Severe 1.47 1.40 1.55 < 0.0001
Palliative care follow-up 2.54 2.35 2.74 < 0.0001
Heart failure liaison service 0.84 0.79 0.88 < 0.0001
GP follow-up 0.60 0.56 0.64 < 0.0001
Care of the elderly follow-up 0.80 0.76 0.85 < 0.0001
Cardiology follow-up 0.60 0.57 0.63 < 0.0001
Previous AMI 1.14 1.09 1.18 < 0.0001
History of diabetes 1.05 1.02 1.08 0.003
History of hypertension 0.93 0.90 0.95 < 0.0001
History of IHD 1.12 1.08 1.16 < 0.0001
History of valvular heart disease 1.24 1.19 1.29 < 0.0001
Age categories (years)
 Min-54 1.00
 55–64 1.43 1.27 1.59 < 0.0001
 65–74 2.02 1.83 2.24 < 0.0001
 75–84 2.74 2.47 3.04 < 0.0001
 85 + 3.68 3.30 4.10 < 0.0001
Male 1.14 1.11 1.17 < 0.0001
LVH 0.86 0.81 0.92 < 0.0001
ACEi/ARB use 0.66 0.64 0.69 < 0.0001
Beta-blocker 0.78 0.75 0.82 < 0.0001
Thiazide 1.12 1.05 1.20 0.001
Loop diuretic 0.72 0.67 0.77 < 0.0001
Digoxin 0.89 0.85 0.92 < 0.0001
Renal failure 1.14 1.08 1.22 < 0.0001
Length of time in hospital (per 5 days) 1.02 1.02 1.03 < 0.0001
Table 4  Multivariate analyses for relation between AF (versus 
sinus rhythm) and in-hospital mortality on imputed data of patients 
recorded as HF (N = 96,593)
HR hazard ratio, CI confidence interval, ECG electrocardiograph, 
NYHA New York Heart Association, AMI acute myocardial infarc-
tion, GP general practitioner, IHD ischaemic heart disease, LVH left 
ventricular hypertrophy, ARB angiotensin receptor blockers, ACI 
angiotensin-converting enzyme inhibitor
HR 95% CI p value
Atrial fibrillation on ECG 1.15 1.09 1.21 < 0.0001
Breathlessness
 NYHA I 1.00
 NYHA II 1.01 0.87 1.18 0.896
 NYHA III 1.10 0.96 1.27 0.18
 NYHA IV 1.32 1.14 1.52 < 0.0001
Peripheral oedema
 None 1.00
 Mild 1.03 0.94 1.13 0.498
 Moderate 1.09 1.01 1.18 0.023
 Severe 1.33 1.22 1.45 < 0.0001
Palliative care follow-up 1.64 1.43 1.89 < 0.0001
Heart failure liaison service 0.51 0.44 0.59 < 0.0001
GP follow-up 0.23 0.19 0.27 < 0.0001
Care of the elderly follow-up 0.44 0.37 0.52 < 0.0001
Cardiology follow-up 0.33 0.28 0.39 < 0.0001
Previous AMI 1.05 0.99 1.11 0.123
History of diabetes 1.01 0.96 1.06 0.799
History of hypertension 0.97 0.92 1.01 0.156
History of IHD 1.08 1.03 1.13 0.003
History of valvular heart disease 1.16 1.10 1.23 < 0.0001
Age categories (years)
 Min-54 1.00
 55–64 1.38 1.13 1.70 0.002
 65–74 1.88 1.55 2.28 < 0.0001
 75–84 2.33 1.90 2.84 < 0.0001
 85 + 2.72 2.21 3.36 < 0.0001
Male 1.06 1.02 1.11 0.003
LVH 0.88 0.80 0.97 0.01
ACEi/ARB use 0.77 0.72 0.83 < 0.0001
Beta-blocker 0.80 0.75 0.86 < 0.0001
Thiazide 0.91 0.78 1.06 0.205
Loop diuretic 0.70 0.65 0.76 < 0.0001
Digoxin 0.70 0.63 0.79 < 0.0001
Renal failure 1.15 1.06 1.25 0.003
Length of time in hospital (per 5 days) 1.02 1.02 1.03 < 0.0001
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and neuroendocrine dysregulation and increased intersti-
tial fibrosis [27]. Despite the well-established association 
between these two conditions, less is known about the effects 
of AF particularly in HFPEF and HFREF on acute and long-
term prognosis in patients hospitalised with heart failure.
Data that examine the relationship between AF and 
clinical outcomes in HF patients have many limitations 
and report inconsistent results. For instance, a retrospective 
analysis of SOLVD (Studies Of Left Ventricle Dysfunction) 
trial suggested that baseline AF was an independent pre-
dictor for all-cause mortality and the combined endpoint 
of death and readmission due to HF in patients who had 
ejection fraction < 35% [28]. Similar results were reported 
in the VALIANT trial (Valsartan in acute myocardial infarc-
tion) where AF was also associated with long-term mortality 
in acute myocardial infarction patients complicated by HF 
[28]. In contrast, a retrospective analysis of the Carvedilol 
or Metoprolol European Trial (COMET) data demonstrated 
that baseline AF significantly increased the risk of death 
and HF hospitalization in patients who had ejection frac-
tion < 35%, although this association lost its significance in 
multivariate analysis [29].
Data around the prognostic impact of AF in patients 
with AHF are more limited. A retrospective analysis of 
Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure (ASCEND-HF) trial showed 
that the patients admitted to hospital with AHF, current 
or background history of AF are independently associ-
ated with lesser dyspnoea improvement, high mortality 
and morbidity (adjusted odds ratio 1.19, CI 1.02–1.38, 
p = 0.029) as compared to those who are in sinus rhythm 
[20]. Furthermore, in GWTG-HF study, the presence of 
AF was an independent predictor of in -hospital mortality 
and more prolonged index hospital admission (> 4 days) 
compared to sinus rhythm. However, in contrast to our 
analysis, no post-discharge mortality data were available. 
Moreover, the present analysis is more robust as compared 
to all other research on this subject as this study demon-
strated that adverse effects of AF remain significant across 
gender and different age groups.
The relationship between AF and clinical outcomes in 
patients with HF may relate to the severity of LV dysfunc-
tion. For instance, Middlekauf et al. reported that AF was 
a stronger predictor of adverse outcomes (total mortality 
and sudden death) in patients with mild to moderate heart 
failure as compared to those with severe heart failure [30]. 
Similarly, Linssen et al. found that AF was associated with 
higher NT-proBNP levels, mortality and morbidity in 
HFPEF but not in HFREF patients [31]. In contrast, in a 
systematic review and meta-analysis of over 54,000 patients, 
Kotecha et al. reported that all-cause mortality was signifi-
cantly higher in patients with AF and HFREF compared to 
HFPEF [32]. Our analysis has suggested that the adverse 
effect of AF remain significant in both HFPEF and HFREF 
in a cohort of 96,000 patients during hospital admission and 
30 days after discharge.
The relationship between AF and outcomes is fur-
ther complicated by the chronicity of AF. For example, 
Table 5  Multivariate analyses for relation between AF (versus sinus 
rhythm) and all deaths on imputed data of patients recorded as HF, 
(N = 96,593)
HR hazard ratio, CI confidence interval, ECG electrocardiograph, 
NYHA New York Heart Association, AMI acute myocardial infarc-
tion, GP general practitioner, IHD ischaemic heart disease, LVH left 
ventricular hypertrophy, ARB angiotensin receptor blockers, ACI 
angiotensin-converting enzyme inhibitor
HR 95% CI p value
Atrial fibrillation on ECG 1.08 1.05 1.12 < 0.0001
Breathlessness
 NYHA I 1.00
 NYHA II 1.07 0.98 1.16 0.123
 NYHA III 1.17 1.07 1.27 < 0.0001
 NYHA IV 1.30 1.19 1.41 < 0.0001
Peripheral oedema
 None 1.00
 Mild 1.08 1.03 1.14 0.002
 Moderate 1.23 1.18 1.29 < 0.0001
 Severe 1.46 1.39 1.53 < 0.0001
Palliative care follow-up 2.48 2.28 2.69 < 0.0001
Heart failure liaison service 0.87 0.83 0.91 < 0.0001
GP follow-up 0.65 0.61 0.69 < 0.0001
Care of the elderly follow-up 0.83 0.78 0.87 < 0.0001
Cardiology follow-up 0.63 0.60 0.66 < 0.0001
Previous AMI 1.13 1.09 1.17 < 0.0001
History of diabetes 1.07 1.04 1.10 < 0.0001
History of hypertension 0.92 0.90 0.95 < 0.0001
History of IHD 1.13 1.09 1.17 < 0.0001
History of valvular heart disease 1.22 1.18 1.26 < 0.0001
Age categories (years)
 Min-54 1.00
 55–64 1.47 1.33 1.62 < 0.0001
 65–74 2.11 1.93 2.31 < 0.0001
 75–84 2.89 2.63 3.18 < 0.0001
 85 + 4.00 3.63 4.41 < 0.0001
Male 1.14 1.11 1.17 < 0.0001
LVH 0.89 0.83 0.94 < 0.0001
ACEi/ARB use 0.68 0.65 0.70 < 0.0001
Beta-blocker 0.78 0.75 0.81 < 0.0001
Thiazide 1.13 1.06 1.20 < 0.0001
Loop diuretic 0.76 0.71 0.81 < 0.0001
Digoxin 0.90 0.87 0.93 < 0.0001
Renal failure 1.13 1.06 1.20 0.002
Length of time in hospital (per 5 days) 1.02 1.02 1.03 < 0.0001
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new-onset and not chronic AF was an independent predic-
tor of all-cause mortality in the EHFS1 and COMET studies 
[33]. As outlined, previous work has suggested that inci-
dent AF has a greater prognostic impact than chronic AF 
and established therapies for HF may reduce the incident 
AF risk. Retrospective analysis of large RCTs suggests that 
ACEI and ARB (angiotensin-converting enzyme inhibitors 
and angiotensin receptor blocker) can reduce the risk of 
incident AF in HF patients [34, 35]. However, this preven-
tive role of ACEI/ARB is less evident in HFPEF [36, 37]. 
Initiation of beta-blocker (BB) therapy in HFREF patients 
who were pre-treated with ACEI/ARB was associated with 
one-third reduction of new-onset AF, [38] although BB does 
not reduce either mortality or hospital admission in patients 
who have HFREF and AF [38, 39]. Eplerenone also reduced 
the risk of incident AF in HF patients with LVEF < 35% 
when added to ACEI/ARB and BB [40]. In our study, a simi-
lar proportion of patients received BB at discharge in both 
groups (63%) but the AF cohort received less ACEI/ARB 
(76% versus 81%).
Limitations
As with any observational study, there are a number of 
limitations. Whilst we have attempted to adjust for differ-
ences in clinical characteristics and patient demographics 
in the current work, the National Heart Failure audit 
does not collect data on co-morbid burden and frailty 
that is known to influence clinical outcomes in patients 
with AHF. Missing data is a common problem in large 
dataset studies which varied in extent depending on the 
study variable. However, we tried to approximate these 
values using multiple imputations to impute the miss-
ing variables. Prior history of AF was not recorded in 
NHFA dataset. Therefore, we are unable to differenti-
ate between new-onset and chronic AF, as some previ-
ous studies report that the adverse prognostic impact of 
AF is limited to new-onset AF [7, 11]. Furthermore, data 
regarding the aetiology of heart failure are not recorded 
in this registry, and so it is unknown whether the prog-
nostic impact of AF differs between the ischaemic and 
non-ischemic aetiologies of HF. Heart Failure with Mid-
range ejection fraction (HFmrEF) is a recently defined 
entity in the European Society of Cardiology (ESC) 2016 
HF guidelines, which encompass those patients who have 
a LVEF of 40–49%, elevated levels of natriuretic peptides 
and either LV hypertrophy, left atrium enlargement or 
diastolic dysfunction [41]. We were unable to analyse our 
dataset for this category as our data were collected before 
this publication [42].
Fig. 3  Sub-group analyses for 
risk of mortality at 30 days in 
AF versus sinus rhythm. HF 
heart failure, LVSD left ventricle 
systolic dysfunction
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Conclusion
The current report, of approximately 100,000 unselected 
emergency hospital admissions due to heart failure, is the 
first to compare survival outcomes in AHF patients in the 
presence or absence of AF during an index hospital admis-
sion, at 30 days and 1 year after discharge, across gender and 
in different age groups. This study reveals that AF is associ-
ated with high mortality in AHF during hospital admission 
and up to 1 year after discharge after taking into account 
many potential confounders. Patients with AF in AHF are a 
high-risk cohort, although it is unclear whether targeting AF 
may improve outcomes in this cohort of patients, or whether 
it represents a marker of disease severity.
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